Imran Nizamuddin
@INizMD
Followers
613
Following
3K
Statuses
1K
Hematology/Oncology fellow at WashU @WUHemeOncFellow via @NU_IntMed | @umkcmedschool grad | Tweets ≠ medical advice
St. Louis, MO
Joined May 2019
Grateful to my mentors @nehamehtashahmd and Nancy Bartlett as well as ASH @ASH_hematology for giving me the opportunity to present our work! #ASH2024
Woot woot! @INizMD @NehaMehtaShahMD presenting their IIS examining acalabrutinib + durvalumab in relapsed CNS lymphoma. @SitemanCenter @WashUOncology @WashUHemOncFell
1
1
25
RT @VincentRK: AQUILA trial for high risk smoldering myeloma published in @NEJM today. @thanosdimop Personally for me, it is a huge mile…
0
95
0
@JOEBENNETTMD @dgermain21 @NehaMehtaShahMD @SitemanCenter @WashUOncology @WashUHemOncFell Thanks, Joe! Sad we didn't get a chance to meet up this weekend!
1
0
0
RT @Eddie_Cliff: Impressive results for CD19 directed ADC loncastuximab tesirine in follicular lymphoma - why was it not developed in FL so…
0
24
0
RT @Eddie_Cliff: ENRICH: ibrutinib+R vs BR or RCHOP IR better PFS than RCHOP but *not* better than BR Reasonable to consider BTKi first l…
0
7
0
RT @dgermain21: Two big lymphoma late breaking abstracts @ASH_hematology #ASH2024 Tafa-R-Len beats R-Len in rel/ref FL
0
13
0
RT @majorajay: Huge SCNSL cohort @JuanAlderuccio @CwynKate #ASH24: - 1173 pts, 45% de novo - mPFS 11 mo, mOS 21 mo (better if de novo: 13 &…
0
7
0
RT @majorajay: My favorite trial as a fellow: the MRD2STOP discontinuation trial by @bdermanmd is now published! Short thread of findings,…
0
13
0
RT @DrAEvens: 👏👏 Kudos to Dr Mitchell Smith and @SitemanCenter Dr Brad Kahl on this large prospective, @eaonc randomized study in #MantleCe…
0
6
0
RT @Othman_Al_Sawaf: Check out our latest paper in @JCO_ASCO on surrogacy of endpoints in 1L #CLL trials! Led by @Sim_Florian, we systemat…
0
23
0
RT @MediHumdani: Omission of Radiotherapy in Primary Mediastinal B-Cell Lymphoma: IELSG37 Trial Results | Journal of Clinical Oncology http…
0
19
0
RT @AaronGoodman33: 2024 ELN AML risk treated with low intensity therapies Good! NPM1 or IDH1 or IDH2 or DDX41 mutated plus FLT3/NRAS/KRA…
0
43
0
RT @syed_abutalibmd: Menin Inhibition With Revumenib for KMT2A-Rearranged Relapsed or Refractory Acute Leukemia (AUGMENT-101) | Journal of…
0
5
0
RT @heMEGirl_MD: Had the opportunity to attempt to “demystify” the fellowship application process with @docbraunstein and @chadinabhan on t…
0
2
0
RT @OncBrothers: Vorasidenib now @FDAOncology approved based off Ph3 #INDIGO for residual/recurrent Gr 2 Astrocytoma/Oligodendroglioma w/ I…
0
28
0
RT @AaronGoodman33: T-cell engager therapy for lymphoma! This free and very comprehensive review from @BloodAdvances on CART and bispeci…
0
58
0
RT @NitinJainMD: 👉👉👉Delighted to share review article on #CLL (with my colleagues Drs Bill Wierda and Susan O’Brien) published in the Journ…
0
56
0
RT @smbenlazar: Venetoclax combined with daunorubicin and cytarabine (2 + 6) in acute myeloid leukemia: Updated results of a phase II trial…
0
30
0
RT @DGlaucomflecken: The most dangerous grift in ophthalmology right now is “glasses are harmful.” People that claim diet, exercise, and a…
0
2K
0